Mechanisms of antibody-mediated acute and chronic rejection of kidney allografts

Current Opinion in Organ Transplantation

Volumn 21, Issue 1, 2016, Pages

  Baldwin, William M ^a   Valujskikh, Anna ^a   Fairchild, Robert L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Antibody mediated rejection; Natural killer cells; Platelets

Indexed keywords

CD20 ANTIGEN; COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C4D; CONNECTIVE TISSUE GROWTH FACTOR; FC RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 1BETA; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; NERVE CELL ADHESION MOLECULE; PERFORIN; RANTES; THROMBOCYTE FACTOR 4; UVOMORULIN; VASCULAR CELL ADHESION MOLECULE 1; ANTIBODY;

ANTIBODY MEDIATED REJECTION; CD4+ T LYMPHOCYTE; GENE EXPRESSION; INNATE IMMUNITY; KIDNEY ALLOGRAFT REJECTION; KIDNEY TRANSPLANTATION; MACROPHAGE; NATURAL KILLER CELL; NONHUMAN; REVIEW; THROMBOCYTE; ACUTE DISEASE; ADVERSE EFFECTS; ALLOGRAFT; ANIMAL; CHRONIC DISEASE; GRAFT REJECTION; HUMAN; IMMUNOLOGY;

ACUTE DISEASE; ALLOGRAFTS; ANIMALS; ANTIBODIES; CHRONIC DISEASE; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION;

EID: 84953638597     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0000000000000262     Document Type: Review

References (74)

1. Djamali A, Kaufman DB, Ellis TM, et al. Diagnosis and management of antibody-mediated rejection: current status and novel approaches. Am J Transplant 2014; 14:255-271.
2. Einecke G, Sis B, Reeve J, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009; 9:2520-2531.
3. Gosset C, Lefaucheur C, Glotz D. New insights in antibody-mediated rejection. Curr Opin Nephrol Hypertens 2014; 23:597-604.
4. Sellares J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012; 12:389-399.
5. Lefaucheur C, Loupy A, Vernerey D, et al. Antibody-mediated vascular rejection of kidney allografts: a population-based study. Lancet 2013; 381:313-319.
6. Michaels PJ, Fishbein MC, Colvin RB. Humoral rejection of human organ transplants. Springer Semin Immunopathol 2003; 25:119-140.
7. Matas AJ, Smith JM, Skeans MA, et al. OPTN/SRTR 2012 Annual Data Report: Kidney. Am J Transplant 2014; 14 (Supplement 1):11-44.
8. Halloran PF, Wadgymer A, Ritchie S, et al. The significance of the anti-class I antibody response. I. Clinical and pathologic features of anti-class I mediated rejection. Transplantation 1990; 49:85-91.
9. Nickeleit V, Andreoni K. The classification and treatment of antibody-mediated renal allograft injury: where do we stand? Kidney Int 2007; 71:7-11.
10. Trpkov K, Campbell P, Pazderka F, et al. Pathologic features of acute renal allograft rejection associated with donor-specific antibody. Analysis using the Banff grading schema. Transplantation 1996; 61:1586-1592.
11. Randhawa P. T-cell-mediated rejection of the kidney in the era of donor-specific antibodies: diagnostic challenges and clinical significance. Curr Opin Organ Transplant 2015; 20:325-332.
12. Sun Q, Liu L-H, Cheng Z, et al. Treatment of early mixed cellular and humoral renal allograft rejection with tacrolimus and mycophenolate mofetil. Kidney Int 2007; 71:24-30.
13. Halloran PF, Chang J, Famulski K, et al. Disappearance of T cell-mediated rejection despite continued antibody-mediated rejection in late kidney transplant recipients. J Am Soc Nephrol 2014; 26:1711-1720.
14. Hidalgo LG, Sellares J, Sis B, et al. Interpreting NK cell transcripts versus T cell transcripts in renal transplant biopsies. Am J Transplant 2012; 12:1180-1191.
15. Hidalgo LG, Sis B, Sellares J, et al. NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: evidence for NK cell involvment in antibody-mediated rejection. Am J Transplant 2010; 10:1812-1822.
16. Crespo M, Yelamos J, Redondo D, et al. Circulating NK-cell subsets in renal allograft recipients with anti-HLA donor specific antibodies. Am J Transplant 2015; 15:806-814.
17. Baldwin WM 3rd, Kasper EK, Zachary AA, et al. Other complement-related diagnostic approaches to antibody-mediated rejection. Am J Transplant 2004; 4:311-318.
18. Bohlson SS, O'Conner SD, Hulsebus HJ, et al. Complement, C1q and C1q-related molecules regulate macrophage polarization. Front Immunol 2014; 5:402.
19. Poon IK, Lucas CD, Rossi AG, Ravichandran KS. Apoptotic cell clearance: basic biology and therapeutic potential. Nat Rev Immunol 2014; 14:166-180.
20. Scott D, Botto M. The paradoxical roles of C1q and C3 in autoimmunity. Immunobiology 2015; S0171-S2985.
21. Barnum SR. C4a: an anaphylatoxin in name only. J Innate Immun 2015; 7:333-339.
22. Coulthard LG, Woodruff TM. Is the complement activation product C3a a proinflammatory molecule? Re-evaluating the evidence and the myth. J Immunol 2015; 194:3542-3548.
23. Chaves LD, Bao L, Wang Y, et al. Loss of CD11b exacerbates murine complement-mediated tubulointerstitial nephritis. PLoS One 2014; 9:e92051.
24. Konrad S, Engling L, Schmidt RE, Gessner JE. Characterization of the murine IgG Fc receptor III and IIB gene promoters: a single two-nucleotide difference determines their inverse responsiveness to C5a. J Biol Chem 207; 282:37906-37912.
25. Naesens M, Li L, Ying L, et al. Expression of complement components differs between kidney allografts from living and deceased donors. J Am Soc Nephrol 2009; 20:1839-1851.
26. Kuo HH, Fan R, Dvorina N, et al. Platelets in early antibody-mediated rejection of renal transplants. J Am Soc Nephrol 2015; 26:855-863.
27. Rahimi S, Qian Z, Layton J, et al. Non-complement-and complement-activating antibodies synergize to cause rejection of cardiac allografts. Am J Transplant 2004; 4:326-334.
28. Wasowska BA, Qian Z, Cangellow DLB E, et al. Passive transfer of alloanti-bodies restores acute cardiac rejection in IgKO mice. Transplantation 2001; 71:727-736.
29. Yamakuchi M, Kirkiles-Smith NC, Ferlito M, et al. Antibody to human leukocyte antigen triggers endothelial exocytosis. Proc Natl Acad Sci USA 2007; 104:1301-1306.
30. Morrell CN, Murata K, Swaim AM, et al. In vivo platelet-endothelial interactions in response to major histocompatibility complex alloantibody. Circ Res 2008; 102:777-785.
31. Kuo HH, Morrell CN, Baldwin WM 3rd. Alloantibody induced platelet responses in transplants: potent mediators in small packages. Hum Immunol 2012; 73:1233-1238.
32. Valenzuela NM, Hong L, Shen X-D, et al. Blockade of P-selectin is sufficient to reduce MHC I antibody-elicited monocyte recruitment in vitro and in vivo. Am J Transplant 2013; 13:299-311.
33. Valenzuela NM, Trinh KR, Mulder A, et al. Monocyte recruitment by HLA IgG-activated endothelium: the relationship between IgG subclass and Fcg RIIa polymorphisms. Am J Transplant 2015; 15:1502-1518.
34. Kirk AD, Morrell CN, Baldwin WM 3rd. Platelets influence vascularized organ transplants from start to finish. Am J Transplant 2009; 9:14-22.
35. Morrell CN, Sun H, Swaim AM, Baldwin WM 3rd. Platelets an inflammatory force in transplantation. Am J Transplant 2007; 7:2447-2454.
36. Schober A, Manka D, von Hundelshausen P, et al. Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. Circulation 2002; 106:1523-1529.
37. Boilard E, Blanco P, Nigrovic PA. Platelets: active players in the pathogenesis of arthritis and SLE. Nat Rev Rheumatol 2012; 8:534-542.
38. Boilard E, Nigrovic PA, Larabee K, et al. Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science 2010; 327:580-583.
39. Cloutier N, Pare A, Farndale RW, et al. Platelets can enhance vascular permeability. Blood 2012; 120:1334-1343.
40. Yeaman MR. Platelets: at the nexus of antimicrobial defence. Nat Rev Microbiol 2014; 12:426-437.
41. Jonnalagadda D, Izu LT, Whiteheart SW. Platelet secretion is kinetically heterogeneous in an agonist responsive manner. Blood 2012; 120:5209-5216.
42. Karshovska E, Weber C, von Hundelshausen P. Platelet chemokines in health and disease. Thromb Haemost 2013; 110:894-902.
43. Weber C, Koenen RR. Fine-tuning leukocyte responses: towards a chemo-kine 'interactome'. Trends Immunol 2006; 27:268-273.
44. Baltus T, von Hundelshausen P, Mause SF, et al. Differential and additive effects of platelet-derived chemokines on monocyte arrest on inflamed en-dothelium under flow conditions. J Leukoc Biol 2005; 78:435-441.
45. Nesmelova IV, Sham Y, Dudek AZ, et al. Platelet factor 4 and interleukin-8 CXC chemokine heterodimer formation modulates function at the quaternary structural level. J Biol Chem 2005; 280:4948-4958.
46. von Hundelshausen P, Koenen RR, Sack M, et al. Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium. Blood 2005; 105:924-930.
47. Scheuerer B, Ernst M, Durrbaum-Landmann I, et al. The CXC-chemokine platelet factor 4 promotes monocyte survival and induces monocyte differentiation into macrophages. Blood 2000; 95:1158-1166.
48. Woller G, Brandt E, Mittelstadt J, et al. Platelet factor 4/CXCL4-stimulated human monocytes induce apoptosis in endothelial cells by the release of oxygen radicals. J Leukoc Biol 2008; 83:936-945.
49. Magil AB, Tinckam K. Monocytes and peritubular capillary C4d deposition in acute renal allograft rejection. Kidney Int 2003; 63:1888-1893.
50. Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 2005; 24:1710-1720.
51. Tinckam K, Djurdjev O, Magil AB. Glomerular monocytes predict worse outcomes after acute renal allograft rejection independent of C4d status. Kidney Int 2005; 68:1866-1874.
52. Dragun D, Hoff U, Park J-K, et al. Ischemia-reperfusion injury in renal transplantation is independent of the immunologic background. Kidney Int 2000; 58:2166-2177.
53. Weyrich AS, McIntyre TM, McEver RP, et al. Monocyte tethering by P-selectin regulates monocyte chemotactic protein-1 and tumor necrosis factor alpha secretion. Signal integration and NF-kappa B translocation. J Clin Invest 1995; 95:2297-2303.
54. Henn V, Slupsky JR, Grafe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391:591-594.
55. Neumann F-J, Marx N, Gawaz M, et al. Induction of cytokine expression in leukocytes by binding of thrombin-stimulated platelets. Circulation 1997; 95:2387-2394.
56. van Gils JM, Zwaginga JJ, Hordihk PL. Molecular and functional interactions among monocytes, platelets, and endothelial cells and their relevance for cardiovascular diseases. J Leukoc Biol 2009; 85:195-204.
57. Gleissner CA, Shaked I, Little KM, Ley K. CXC chemokine ligand 4 induces a unique transcriptome in monocyte-derived macrophages. J Immunol 2010; 184:4810-4818.
58. Chinetti-Gbaguidi G, Colin S, Staels B. Macrophage subsets in atherosclerosis. Nat Rev Cardiol 2015; 12:10-17.
59. Duerschmied D, Suidan GL, Demers M, et al. Platelet serotonin promotes the recruitment of neutrophils to sites of acute inflammation in mice. Blood 2013; 121:1008-1015.
60. Nimmerjahn R, Ravetch JV. Fc gamma receptors as regulators of immune responses. Nat Rev Immunol 2008; 8:34-47.
61. Pincetic A, Bournazos S, DiLillo DJ, et al. Type I and type II Fc receptors regulate innate and adaptive immunity. Nat Immunol 2014; 15:707-716.
62. Gillis C, Gouel-Cheron A, Jonsson F, Bruhns P. Contribution of human FcgRs receptors to disease with evidence from human polymorphisms and transgenic animal studies. Front Immunol 2014; 5:254.
63. Du Clos TW, Mold C. Pentraxins (CRP, SAP) in the process of complement activation and clearance of apoptotic bodies through Fc gamma receptors. Curr Opin Organ Transplant 2011; 16:15-20.
64. Erdinc Sunay MM, Fox-Talbot K, Velidedeoglu E, et al. Absence of Fc gamma RII results inincreased proinflammatoryresponse in Fc gamma RII-KO cardiac recipients. Transplantation 2013; 96:601-608.
65. Hirohashi T, Chase CM, Della Pelle P, et al. A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody. Am J Transplant 2012; 12:313-321.
66. Clatworthy MR, Matthews RJ, Doehler B, et al. Defunctioning polymorphism in the immunoglobulin G inhibitor receptor (FcgRiiB-T/T232) does not impact on kidney transplant or recipient survival. Transplantation 2014; 98:285-291.
67. Shin BH, Ge S, Mirocha J, et al. Regulation of anti-HLA antibody-dependent natural killer cell activation by immunosuppresive agents. Transplantation 2014; 97:294-300.
68. Bickerstaff AA, Wang J-J, Pelletier RP, Orosz CG. Murine renal allografts: spontaneous acceptance is associated with regulated T cell-mediated immunity. J Immunol 2001; 167:4821-4827.
69. Russell PS, Chase CM, Colvin RB, Plate JMD. Kidney transplants in mice. An analysis of the immune status of mice bearing long-term, H-2 incompatible transplants. J Exp Med 1978; 147:1449-1468.
70. + cells. Am J Pathol 2011; 178:1635-1645.
71. - recipients. Am J Transplant 2008; 8:557-566.
72. Gorbacheva V, Fan R, Wang X, et al. IFN-7 production by memory helper T cells is required for CD40-independent alloantibody responses. J Immunol 2015; 194:1347-1356.
73. Rabant M, Gorbacheva V, Fan R, et al. CD40-independent help by memory CD4 T cells induces pathogenic alloantibody but does not lead to long-lasting humoral immunity. Am J Transplant 2013; 13:2831-2841.
74. Abe T, Ishii D, Gorbacheva V, et al. Anti-huCD20 antibody therapy for antibody-mediated rejection of renal allografts in a mouse model. Am J Transplant 2015; 15:1192-1204.